PR Newswire Asia's news > Biotechnology

 < Previous page   |   Title only   |   Print    Next page > 
     
Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy
NVC-001 is designed to target the mechanobiological root cause of LMNA dilated cardiomyopathy and has disease-modifying potential ...
2026-10-08T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
LOTTE Biologics and Alvotech announce US-based manufacturing agreement to increase global supply
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York ...
2026-10-08T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Sisram Medical Announces Share Repurchase Plan for Up to 1% of Issued Shares
Reinforcing Confidence in Long-Term Growth and Commitment to Shareholder Returns ...
2026-10-08T    Biotechnology   Cosmetics & Personal Care   Health Care/Hospital   Medical Equipment 
Löviselle LEAP Advances Across Singapore and Malaysia: Building a Regional Platform for Bio-Active Regeneration
KUALA LUMPUR, Malaysia , Oct. 8, 2026 /PRNewswire/ -- Following the inaugural LEAP at a leading Singapore Medical Academy, Löviselle convened the first Malaysian LEAP at the Medical Academy of Malaysia. ...
2026-10-08T    Biotechnology   Cosmetics & Personal Care   Health Care/Hospital   Medical/Pharmaceuticals 
Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133
SUZHOU, China and MÖLNDAL, Sweden , Oct. 8, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") ...
2026-10-08T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability
SHANGHAI , Oct. 8, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received a Gold medal from EcoVadis for ...
2026-10-08T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
OCI N.V. Notes Enterprise Chamber Decision Not to Order Inquiry
AMSTERDAM , Oct. 8, 2026 /PRNewswire/ -- OCI N.V. ("OCI" or the "Company") (Euronext: OCI) notes that the Enterprise Chamber of the Amsterdam Court of Appeal has today dismissed ...
2026-10-08T    Banking/Financial Service   Biotechnology   Chemical 
Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex for CEVIRA® subject to certain conditions, Advancing the Global Development and Commercialization of a Non-Surgical Treatment for Cervical Precancerous Lesions in Europe
Agreement is expected to grant Theramex exclusive rights to CEVIRA ® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for the rest of the world. The deal includes ...
2026-10-07T    Biotechnology   Medical/Pharmaceuticals 
Resonant Clinical Solutions and Haier Biomedical Introduce an Innovative Benchtop Centrifuge with a Natural Refrigerant
Exclusive partnership results in a user-centric, hydrocarbon-cooled centrifuge purpose-built for clinical trials – years ahead of upcoming F-gas regulatory changes in Europe and the U.S. ...
2026-10-07T    Biotechnology   Computer/Electronics   Environmental Products & Services   Health Care/Hospital 
LG CNS Showcases Pharma-Specific Manufacturing AX at World's Largest Pharma-Biotech Show
Participates in CPHI Milan 2026, Expanding Manufacturing AX Reach in Pharma Showcasing key solutions for factory design, production operations, and quality management using the theme "Autonomous ...
2026-10-07T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.